featured
Maintenance With Daratumumab or Observation Following Induction Treatment and Auto-SCT in Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Lancet Oncol 2021 Sep 13;[EPub Ahead of Print], P Moreau, C Hulin, A Perrot, B Arnulf, K Belhadj, L Benboubker, MC Béné, S Zweegman, H Caillon, D Caillot, J Corre, M Delforge, T Dejoie, C Doyen, T Facon, C Sonntag, J Fontan, M Mohty, KS Jie, L Karlin, F Kuhnowski, J Lambert, X Leleu, M Macro, F Orsini-Piocelle, M Roussel, AM Stoppa, NWCJ van de Donk, S Wuillème, A Broijl, C Touzeau, M Tiab, JP Marolleau, N Meuleman, MC Vekemans, M Westerman, SK Klein, MD Levin, F Offner, M Escoffre-Barbe, JR Eveillard, R Garidi, T Ahmadi, M Krevvata, K Zhang, C de Boer, S Vara, T Kampfenkel, V Vanquickelberghe, J Vermeulen, H Avet-Loiseau, P SonneveldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.